HIF PHD Inhibitors
Items 1 to 10 of 13 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2,4-Diethylpyridine dicarboxylate | 41438-38-4 | sc-202405 sc-202405A | 10 mg 25 mg | $21.00 $67.00 | ||
2,4-Diethylpyridine dicarboxylate exhibits a remarkable capacity to modulate hypoxia-inducible factor (HIF) pathways by acting as a potent inhibitor of prolyl hydroxylase domain (PHD) enzymes. This compound's unique structural features allow it to effectively disrupt the hydroxylation of HIF-1α, leading to its accumulation. The resulting alterations in cellular signaling dynamics significantly impact gene expression related to oxygen homeostasis, enhancing adaptive responses to hypoxic conditions. | ||||||
N-Oxalyl-L-alanine | 5302-46-5 | sc-205959 sc-205959A | 10 mg 50 mg | $42.00 $125.00 | ||
N-Oxalyl-L-alanine serves as a selective inhibitor of prolyl hydroxylase domain (PHD) enzymes, influencing the stability of hypoxia-inducible factors (HIFs). Its unique molecular structure facilitates specific interactions with the active site of PHDs, effectively preventing the hydroxylation of HIF-1α. This inhibition alters the kinetics of HIF signaling, promoting a shift in cellular metabolism and enhancing the organism's ability to respond to fluctuating oxygen levels. | ||||||
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $82.00 $295.00 $367.00 $764.00 | 25 | |
DMOG competes with 2-oxoglutarate for binding to HIF PHD, reducing its enzymatic activity and thus preventing HIF-α hydroxylation. | ||||||
GSK360A | 931399-19-8 | sc-490346 sc-490346A sc-490346B sc-490346C | 5 mg 10 mg 25 mg 50 mg | $355.00 $648.00 $1474.00 $2516.00 | 1 | |
GSK360A is a potent inhibitor of prolyl hydroxylase domain (PHD) enzymes, characterized by its ability to disrupt the hydroxylation process of hypoxia-inducible factors (HIFs). Its unique binding affinity allows for selective interaction with the PHD active site, modulating the enzymatic reaction kinetics. This alteration in enzymatic activity leads to significant changes in cellular oxygen sensing pathways, ultimately influencing metabolic adaptation under varying hypoxic conditions. | ||||||
IOX2 | 931398-72-0 | sc-482692 sc-482692A sc-482692B | 5 mg 25 mg 100 mg | $128.00 $555.00 $1581.00 | ||
IOX2 is a potent inhibitor of HIF PHD that promotes HIF-α stabilization by preventing its hydroxylation. | ||||||
N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine-d3 | 808118-40-3 unlabeled | sc-488006 | 10 mg | $12000.00 | ||
Roxadustat inhibits HIF PHD, resulting in HIF-α stabilization. | ||||||
BAY 85-3934 | 1154028-82-6 | sc-507384 | 5 mg | $205.00 | ||
Molidustat is a HIF PHD inhibitor that promotes the stabilization of HIF-α by preventing its hydroxylation. | ||||||
Deferoxamine mesylate | 138-14-7 | sc-203331 sc-203331A sc-203331B sc-203331C sc-203331D | 1 g 5 g 10 g 50 g 100 g | $255.00 $1039.00 $2866.00 $4306.00 $8170.00 | 19 | |
This iron chelator can inhibit HIF PHD by depleting its necessary co-factor, iron, preventing HIF-α hydroxylation. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $63.00 $173.00 | 7 | |
CoCl2 inhibits HIF PHD activity by replacing the iron ion in the active site, leading to HIF-α stabilization. | ||||||
Protocatechuic acid ethyl ester | 3943-89-3 | sc-236496 | 5 g | $32.00 | ||
This compound is a prodrug that releases carbon monoxide (CO) which can inhibit HIF PHD activity, leading to HIF-α stabilization. | ||||||